- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02013479
Selenium Supplementation in Autoimmune Thyroiditis (CATALYST)
The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Chronic autoimmune thyroiditis (AIT) is a common autoimmune disease that often leads to impaired function of the thyroid gland, increases in incidence with age, and has an 8-9 time female preponderance. Quality of life is often impaired and complaints persist in a considerable number of patients, even after restoration of euthyroidism. The autoimmune component of the disease has been suggested as an explanation for this. Selenium is a micro nutritive essential for human health and the thyroid gland has the highest selenium concentration of all human tissues. Selenoproteins catalyse thyroid hormone metabolism and anti-oxidative processes in thyrocytes. In addition they are important to immune function. In Denmark, patients with AIT have lower blood selenium concentration than the background population. The majority of 13 randomised trials have shown that selenium supplementation decreases serum thyroid peroxidase antibody levels (TPO-Ab) in patients with AIT, when compared with placebo. We hypothesise that adjuvant selenium may be beneficial in the treatment of AIT.
Objectives: To investigate if selenium supplementation versus placebo adjuvant to the standard treatment with levothyroxine (LT4) in patients with AIT will lead to improved thyroid specific quality of life, and reduced autoimmune activity.
Design and trial size: The CATALYST trial is an investigator-initiated randomised, blinded, multicentre clinical trial of selenium supplementation versus placebo in patients with AIT. The trial will include 472 participants (2 X 236) from four clinical trial sites.
Intervention and duration: The experimental intervention group will receive 200 μg selenium-enriched yeast as two oral tablets once daily for 12 months. The control group will receive two placebo tablets, identical in appearance, taste and smell, once daily for 12 months. Six months additional follow-up leads to a trial duration of 18 months. The experimental supplement will be SelenoPrecise® by Pharma Nord ApS.
Time schedule: July 2012 - February 2014: preparation, approval and trial registration . March 2014: first participant first visit. March 2016: last participant first visit. September 2017: last participant last visit. Autumn 2017: analysis of biological samples and data, preparation of manuscripts.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark
- Clinic of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet
-
Copenhagen, Denmark
- Department of Endocrinology and Gastroenterology, Bispebjerg Hospital
-
Esbjerg, Denmark
- Department of Internal Medicine, Hospital of South West Denmark
-
Odense, Denmark
- Department of Endorcrinology and Metabolism, Odense University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years.
- Serum-TPO-Ab ≥ 100 IU/mL measured within the last 12 months.
Receiving LT4 treatment.
- Serum-TSH ≥ 4.0 mU/L measured prior to treatment initiation
- Written informed consent.
Exclusion Criteria:
- Previous diagnosis of toxic nodular goitre, Graves' hyperthyroidism, post-partum thyroiditis or thyroid associated orbitopathy (TAO).
- Previous radioiodine therapy, anti-thyroid treatment or thyroid surgery.
- Previous diagnosis of non-melanoma skin cancer.
- Morbidity, rendering the participant unable to process patient reported outcomes or receive intervention during the trial.
- Systemic immunomodulatory medication.
- Other medication known to affect thyroid function.
- Pregnancy, breastfeeding, or planned pregnancy within 18 months.
- Allergy towards the components in the selenium or placebo pills.
- Intake of selenium supplementation ≥ 55 μg/d.
- Unable to read or understand Danish.
- Lack of informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Produced by Pharma Nord ApS, Vejle, Denmark
|
Experimental: SelenoPRECISE
|
Produced by Pharma Nord ApS, Vejle, Denmark
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thyroid related quality of life
Time Frame: 12 months after initation of intervention
|
Measured in composite score based on the ThyPRO questionnaire
|
12 months after initation of intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Thyroid peroxidase antibody concentration (TPO-Ab)
Time Frame: 12 months after initation of intervention
|
12 months after initation of intervention
|
Levothyroxine (LT4) dosage
Time Frame: 12 months after initation of intervention
|
12 months after initation of intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steen J Bonnema, MD, DMSc, Odense University Hospital
- Principal Investigator: Laszlo Hegedüs, MD, DMSc, Odense University Hospital
- Principal Investigator: Kristian H Winther, MD, Odense University Hospital
- Principal Investigator: Torquil Watt, MD, PhD, Rigshospitalet, Denmark
- Principal Investigator: Per Cramon, MD, Rigshospitalet, Denmark
- Principal Investigator: Åse K Rasmussen, MD, DMSc, Rigshospitalet, Denmark
- Principal Investigator: Jeppe Gram, MD, PhD, Hospital of South West Jutland
- Principal Investigator: Nils J Knudsen, MD, DMSc, Bispebjerg Hospital, Denmark
- Principal Investigator: Ulla Feldt-Rasmussen, MD, DMSc, Rigshospitalet, Denmark
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DK-CATALYST
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Thyroiditis
-
Ege UniversityCompletedAutoimmune Thyroiditis | Hashimotos ThyroiditisTurkey
-
University of SienaIBSA Institut Biochimique SAUnknownThyroiditis Autoimmune
-
Aristotle University Of ThessalonikiCompletedAutoimmune ThyroiditisGreece
-
University of BucharestCompleted
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Assiut UniversityCompletedAutoimmune Thyroiditis
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento... and other collaboratorsCompleted
-
Beijing Chao Yang HospitalRecruiting
-
First Affiliated Hospital of Harbin Medical UniversityUnknown
-
Medical University of GdanskNutricia FoundationCompleted
Clinical Trials on SelenoPRECISE
-
Wageningen UniversityWorld Cancer Research Fund InternationalCompletedProstatic Neoplasms | Prostate CancerNetherlands
-
Odense University HospitalDanish Cancer Society; University of Southern Denmark; Pharma Nord; K. A. Rohde... and other collaboratorsCompleted
-
University Hospital, LinkoepingThe Swedish Research Council; Ostergotland County Council, Sweden; Pharma NordCompletedCardiac Function | Cardiovascular MortalitySweden
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity of Bologna; Azienda Usl di BolognaEnrolling by invitation